CRK and cancer: The domain structure of PEAK1 has predicted consensus binding and/or substrate sites for Src, Erk, Shc and Crk and can operate within Src-p130Cas-Crk-Paxillin and Ras-Raf-Erk signaling pathways to regulate cell proliferation, migration and cancer progression [12,13].